Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disease, affecting 1:400 to 1:1000 of the population. 1 It accounts for around 10% of patients with end-stage renal disease (ESRD) requiring renal replacement therapy (RRT).
ADPKD is a multi-systemic disorder with cystic and non-cystic manifestations. It is characterized by progressive formation and enlargement of cysts in the kidneys. The symptoms of ADPKD typically begin in the third and fourth decade of life. 2 Although the phenotype is fully penetrant, there is significant interfamilial and intrafamilial variability. The major risk factors determining disease progression are still not well understood.
The main objective of this study was to study the natural history of disease progression in a cohort of ADPKD patients seen at the Sheffield Kidney Institute between 1978 and 2012.
Methodology
We performed a retrospective analysis of renal function from all ADPKD patients (n = 565) recorded on a renal database 'Proton' at the Sheffield Kidney Institute. Those who had reached ESRD with at least 5 years of renal function tests prior to the study end point were included in the analysis as the ESRD group (n = 113). The study end point was defined by the onset of ESRD (transplantation, dialysis or death from ESRD). This cohort was compared with patients being followed-up in a dedicated polycystic kidney disease (PKD) clinic (n = 210) who had at least 5 years renal function tests at the time of analysis (PKD clinic group, n = 88).
Estimated glomerular filtration rate (eGFR) was calculated from serum creatinine using the abbreviated four-factor modification of diet in renal disease (MDRD) equation. All eGFR results for each patient were plotted over time on a graph. Assuming the rate of decline in renal function (ÁeGFR, expressed in ml/min/1.73 m 2 /year) is a constant regression, a linear equation was determined. The rate of eGFR decline was represented by the slope of the line, based on a minimal of five eGFR results within the past 5-year period prior to the study. Where available, every 5 years of eGFR decline was calculated retrospectively until the earliest record available from the renal database.
A subgroup analysis of the 210 patients in the PKD clinic was performed to identify potential risk factors predicting renal disease progression. Clinical information from the ESRD group was not included due to limited availability of retrospective data. All patients in the PKD clinic underwent standard history and physical examination by a single physician. Demographic parameters, clinical characteristics, laboratory investigations and radiological findings were recorded where available. Subjects were considered to have macroscopic haematuria by self-reporting. Proteinuria was significant if the urine protein creatinine ratio (uPCR) was >50 mg/mmol. The incidence of at least one episode of urinary tract infection (UTI) (either culture positive or negative) was classified as positive for infection. Recorded renal lengths from routine abdominal ultrasounds were available for 88 patients. The mean kidney length was calculated from the average lengths of left and right kidneys. Diagnosis of liver cystic disease required the presence of at least one cyst on ultrasound. The variation in age at ESRD for other deceased and living family members of patients was recorded from self-reported information.
All data were analysed by using SPSS software package. A non-parametric test (Mann-Whitney U-test) was used to compare the age, follow-up duration and rate of decline in eGFR of both ESRD and PKD clinic groups as the data were not normally distributed. Categorical variables such as gender distribution were analysed using 2 tests. In subgroup analysis of the PKD clinic group, univariate linear regression was used to determine the correlation coefficient (r) of the mean kidney length and age at diagnosis with ÁeGFR. A mixed model was built to assess the effect of all the predictive variables with respect to the rate of decline in eGFR. A probability value <0.05 was considered to be statistically significant.
Results
The clinical characteristics of all patients studied are shown in Table 1 . The ESRD and PKD clinic groups were comparable in age (at first entry to the renal database) and gender. However, the mean followup duration was significantly longer in the PKD clinic group (13.9 AE 7.3 vs. 11.3 AE 5.5 years).
As shown in Figure 1 , the overall ÁeGFR was higher in the ESRD group (4.19 AE 1.66 ml/min/ 1.73 m 2 /year) compared with the PKD clinic group (1.71 AE 1.36 ml/min/1.73 m 2 /year). The difference was statistically significant at a level of P < 0.0001. Figure 2 further illustrates the trend of decline in renal function of both groups of patients throughout their follow-up in 5-year intervals, retrospectively up to 20 years. A significant difference in ÁeGFR for each 5-year period between both groups was observed up to 10 years prior to ESRD or analysis. There was an increasing trend in ÁeGFR even 20 years beforehand especially in the ESRD group. Table 2 summarizes the demographic data and clinical characteristics of the 210 patients in the PKD clinic. A positive family history of ADPKD was present in 165 (78.6%) patients. There was an equal gender ratio with 48.6% males and 51.4% females. The mean age at the time of diagnosis was 34.45 (AE16.71) years. Patients with a positive family history of ADPKD were diagnosed at a significantly younger age than those without a family history: median age of 30 vs. 43.5 years old, respectively. The majority (37.6%) were asymptomatic and diagnosed via screening due to a positive family history. As for symptomatic patients at first presentation, lumbar/abdominal pain was the most frequent symptom (18.6%) followed by hypertension (12.9%). Hypertension or raised serum creatinine was more commonly found to be the initial presentation in the older age group. There were more female patients initially presenting with lumbar pain than male patients (P < 0.05). On the other hand, more males had haematuria as the initial presentation compared with females (P < 0.05).
Hypertension was the most common clinical finding which occurred in 147 (70%) patients. The majority (40.8%) were on a single agent with angiotensin-converting enzyme inhibitors being the most commonly prescribed class (51%), followed by calcium channel blockers (44.9%). In addition, hypertension was significantly associated with a greater mean kidney length detected on ultrasound (P < 0.05) (Figure 3) . By comparing the latest eGFR result, patients with hypertension had a significant lower eGFR (median: 47 ml/min/1.73 m 2 ) compared with normotensive patients (median: 84 ml/min/ 1.73 m 2 ). Clinically, 42.4% of patients had palpable kidneys on physical examination. Microscopic haematuria and proteinuria (uPCR >50 mg/mmol) were present in 23 (11%) and 12 (5.7%) patients, respectively. No patients had nephrotic range proteinuria. Around 27% of patients had suffered from at least one episode of UTI. The prevalence of UTIs was significantly higher among females (P < 0.05). Lumbar/abdominal pain was reported by 25.7% of patients. There were significantly more female patients complained of pain (P < 0.05).
Regarding extra-renal manifestations, there were 117 (55.8%) patients with liver cysts detected on ultrasound. The prevalence of liver cysts was significantly higher in females (P < 0.05). Pancreatic cysts were detected in only 1% cases although 20.5% of patients had obscured views of the pancreas on ultrasound scanning.
The factors affecting the renal disease progression were determined by using the last 5-year eGFR results prior to the study. Only 55 patients included in the analysis due to the limited number of patients with recorded kidney lengths on ultrasound and 5-year eGFR results. By regression analysis, the rate of decline in eGFR was significantly but inversely correlated (r = À0.44) with the age of diagnosis ( Figure 4 ). There was also a weak correlation between the mean kidney length (r = 0.28) and ÁeGFR in the univariate analysis. Other potential risk factors such as gender, hypertension, haematuria, proteinuria, UTI and liver cysts were not significantly associated with ÁeGFR in this cohort. By multivariate linear regression analysis (Table 3) , mean kidney length (x 1 ) and age of diagnosis (x 2 ) were predictors for ÁeGFR (y), with y = 2.054 + 0.112x 1 À 0.048x 2 (where r 2 = 0.237 and P < 0.05). Figure 5 shows the age at ESRD of 27 pedigrees with at least two family members diagnosed with ESRD. In one example (Pedigree 102), the age at ESRD ranged from 30 to 64 years. The phenotypic variability within the same family and between pedigrees is well illustrated. 
Discussion
ADPKD is caused by germline mutations in either PKD1 (chromosome 16p13.3) or PKD2 (4q21).
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PKD1 mutations account for 85% of cases in clinically identified populations. 6 Patients with PKD2 mutations generally have a milder phenotype compared with those with PKD1. 7, 8 Although the gene locus involved is a major determinant of disease severity, allelic effects, environmental factors and other genetic modifiers play important roles. 9 In our study, intrafamilial variability was clearly Figure 4 . Correlation of rate of decline in eGFR (ÁeGFR) with age at first diagnosis and estimated mean kidney length in 55 patients being followed-up in the PKD clinic. Multivariate linear regression analysis: y = 2.054 + 0.112x 1 -0.048x 2 (where y = ÁeGFR, x 1 = mean kidney length, x 2 = age of diagnosis, r 2 = 0.237 and P < 0.05).
seen by assessing the age at ESRD among all the family members within the same pedigree (shown in Figure 5 ). Recently, the vasopressin V2-receptor antagonist, tolvaptan was shown to slow the rate of increase in total kidney volume and decline in kidney function over a 3-year period. 10 Other ongoing clinical trials of treatment for ADPKD include long acting somatostatins, mammalian target of rapamycin (mTOR) inhibitors and others. 11 It is therefore important to understand the natural history of ADPKD to identify patients who would benefit from early treatment intervention.
Previous reports indicate that the rate of GFR decline in ADPKD can vary significantly in different studies, depending on the selected cohort as well as the study duration. One large US study of 229 subjects reported a mean annual decline in GFR at 2.4 ml/min/1.73 m 2 /year. 12 Higashihara et al. estimated the eGFR slope in a Japanese cohort of 196 patients with a median observation of 3.3 years. In their series, the rate of decline in eGFR was 3.4 ml/min/1.73 m 2 /year but was not statistically different between different stages of CKD. 13 Their findings differ from ours, in that there was an increasing trend in ÁeGFR over time. We were able to study the majority of patients over a longer duration of observation with a median interval of >10 years.
In another study involving 109 patients who reached ESRD and 48 undialysed CKD (Stage 3) patients, the annual rate of decline of creatinine clearance (Ccr) was reported as 5.8 and 5.3 ml/min/ 1.73 m 2 /year, respectively. 14 In contrast, we found a much slower rate of decline in eGFR in the undialysed group (1.71 AE 1.36 ml/min/1.73 m 2 /year). There was a significant difference in ÁeGFR between patients requiring ESRD and those in long-term clinic follow-up although there was a similar age and gender distribution in both groups. The most likely explanation is we included a greater number of patients from all stages of CKD.
Our study also demonstrated that rapid and slower progressors had been segregated by natural selection. In the ESRD group, the eGFR started to decline significantly at $10 years before study end point (Figure 2 ). It has been reported that renal function remains normal in most patients until the fourth to sixth decade of life, but rapidly declines at 4.4-5.9 ml/min/year in the decade or so preceding ESRD. 9 We however noted a decline in kidney function even 20 years prior to the onset of ESRD. This may allow the stratification of high-risk patients for treatment.
A weak but significant correlation between the rate of decline in eGFR and mean kidney length measured by ultrasound (r = 0.28) was observed in the PKD clinic group. This finding is in agreement with Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) 15, 16 and other published data. 12, 17 The CRISP investigators measured total kidney and cyst volumes by magnetic resonance imaging annually in a selected cohort aged between 15 and 46 years old with measured or estimated Ccr of 570 ml/min. They found that kidney and cyst volumes were the strongest predictors of renal functional decline. Total kidney volume and total cyst volume increased exponentially and higher rates of kidney enlargement are associated with more rapid decline in renal function. Compared with the CRISP study, we included patients with different levels of eGFR reflecting 'reallife' current clinical practice. We also demonstrated that ÁeGFR was significantly and inversely correlated (r = À0.44) with the age of diagnosis. Younger age at presentation has been recognized as a predictor of poorer renal outcome in several published studies. 12, 17, 18 An increase in blood pressure usually precedes renal impairment, with an average age onset of 30 years 19, 20 and there is an increasing prevalence of hypertension with decreasing renal function. We noted that hypertensive ADPKD patients had a significantly lower eGFR compared with normotensive patients but did not observe a significant correlation with ÁeGFR as previously reported. 17, 20 Other clinical factors reported to be associated with more rapid disease progression are male gender, episodes of macroscopic haematuria, overt proteinuria (>300 mg/day), three or more pregnancies and hepatic cysts in women. 17, [21] [22] [23] We did not elicit these relationships in our PKD clinic cohort possibly because they represent a group with slower progression and milder clinical phenotypes. Further studies in a larger population representing the full phenotypic spectrum of disease in ADPKD will be needed to clarify these points.
Conclusion
This study is one of the longest natural history studies in ADPKD (>30 years). The rate of decline in eGFR was significantly correlated to mean kidney size and age of diagnosis. The difference in ÁeGFR could be predicted at least 10 years prior to the onset of ESRD and thus will enable higher risk patients to be identified early for treatment. Further longitudinal studies in larger populations of patients will be needed to establish the role of other risk factors in modifying renal function in this disease.
